文献速递血栓与止血

根据基线危险因素特征分类的复发性静脉血栓栓塞风险

Risk of recurrent venous thromboembolism according to baseline risk factor profiles.
PubMed 文献 · Blood Adv · 2018-01-01

该预设分析利用两项随机试验数据,比较每日一次利伐沙班(20 mg或10 mg)与阿司匹林(100 mg)或安慰剂延长治疗VTE的复发风险。共2832例接受利伐沙班、1131例接受阿司匹林、590例接受安慰剂。无诱因VTE患者1年复发率在利伐沙班组、阿司匹林组和安慰剂组分别为2.0%、5.9%和10.0%;由主要一过性危险因素诱发的VTE无复发。作者认为由次要持续或次要一过性危险因素诱发的VTE患者也可能从延长抗凝治疗中获益。

要点

  • 无诱因VTE患者1年复发率:利伐沙班组2.0%、阿司匹林组5.9%、安慰剂组10.0%。
  • 由主要一过性危险因素诱发的VTE患者无复发。
  • 由次要持续或次要一过性危险因素诱发的VTE复发率与无诱因VTE相比无显著降低。

核心结论

  • 由次要持续或次要一过性危险因素诱发的VTE患者复发率与无诱因VTE相比无显著降低,作者认为这类患者也可能从延长抗凝治疗中获益。

研究设计与样本

  • 预设分析,使用两项随机试验的数据,比较每日一次利伐沙班(20 mg或10 mg)与阿司匹林(100 mg)或安慰剂延长治疗VTE的复发风险。
  • 共2832例患者接受利伐沙班,1131例接受阿司匹林,590例接受安慰剂。
  • 索引VTE事件经中心分类为无诱因、由主要一过性或持续性危险因素诱发、或由次要一过性或持续性危险因素诱发,并计算1年复发率。

主要发现

  • 无诱因VTE患者中,接受利伐沙班的1173例、阿司匹林的468例和安慰剂的243例的1年复发率分别为2.0%、5.9%和10.0%。
  • 由主要一过性危险因素诱发的VTE患者无复发。
  • 由次要持续危险因素诱发的VTE患者中,接受利伐沙班的1184例、阿司匹林的466例和安慰剂的248例的1年复发率分别为2.4%、4.5%和10.7%。
  • 由次要一过性危险因素诱发的VTE患者中,接受利伐沙班的268例、阿司匹林的121例和安慰剂的56例的1年复发率分别为0.4%、4.2%和7.1%。
  • 由次要持续或次要一过性危险因素诱发的VTE患者复发率与无诱因VTE相比无显著降低(风险比[HR] 0.81,95%置信区间[CI] 0.56-1.16;HR 0.68,95% CI 0.32-1.30)。

临床怎么用

  • 作者认为,由次要持续或次要一过性危险因素诱发的VTE患者也可能从延长抗凝治疗中获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The optimal duration of anticoagulation for venous thromboembolism (VTE) is uncertain. In this prespecified analysis, we used data from 2 randomized trials, which compared once-daily rivaroxaban (20 mg or 10 mg) with aspirin (100 mg) or placebo for extended VTE treatment to estimate the risk of recurrence according to baseline risk factor profiles. Index VTE events were centrally classified as unprovoked, or provoked by major transient or persistent, or minor transient or persistent risk factors, and rates of recurrence at 1 year were calculated. A total of 2832 patients received rivaroxaban; 1131 received aspirin, and 590 received placebo. With unprovoked VTE, rates of recurrence in the 1173 patients given rivaroxaban, the 468 given aspirin, and the 243 given placebo were 2.0%, 5.9%, and 10.0%, respectively. There were no recurrences in patients with VTE provoked by major transient risk factors. With VTE provoked by minor persistent risk factors, recurrence rates in the 1184 patients given rivaroxaban, the 466 given aspirin, and the 248 given placebo were 2.4%, 4.5%, and 10.7%, respectively. For patients with minor transient risk factors, recurrence rates were 0.4% in the 268 patients given rivaroxaban, 4.2% in the 121 given aspirin, and 7.1% in the 56 given placebo. Recurrence rates in patients with VTE provoked by minor persistent or minor transient risk factors were not significantly lower than that with unprovoked VTE (hazard ratio [HR], 0.81; 95% confidence interval [CI], 0.56-1.16; and HR, 0.68; 95% CI, 0.32-1.30, respectively). Therefore, such patients may also benefit from extended anticoagulation therapy.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Prins MH, Lensing AWA, Prandoni P, et al. Risk of recurrent venous thromboembolism according to baseline risk factor profiles. Blood Adv. 2018. PMID: 29632234. doi:10.1182/bloodadvances.2018017160

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。